Merck's CEO Doesn't Think That Valuations In The Biotech Industry Are 'Rich' By: Benzinga via Benzinga December 08, 2014 at 12:46 PM EST Merck & Co., Inc. (NYSE: MRK)announced that it has agreed to acquire Cubist Pharmaceuticals Inc (NASDAQ: CBST) for $9.5 ... Read More >> Related Stocks: Merck & Co